Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-11-06
2007-11-06
Kwon, Brian (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S301000, C514S302000, C514S469000
Reexamination Certificate
active
10171056
ABSTRACT:
This invention provides methods of inhibiting plasminogen activator inhibitor-1 (PAI-1) in a mammal, utilizing compounds of the formula:wherein: A is C or N; B is O, S, N, or CH═CH;X is CO, CH(OH), CH2, or —CH—S-2-benzothiazole; Y is H, alkyl, or halo; Z is O, S, or N;R is H, nitro, alkyl, alkoxy, halo, or CF3; R1is alkyl, aryl, aralkyl, halo, Het-alkyl, or optionally substituted aryl;Het isG is O, S, or N; R2is H, halo, alkyl, or —OR5; R3and R4are H, halo, alkyl, aryl, nitro, amino, alkylsulfoamide, arylsulfoamide, cycloalkyl, heterocycle, or optionally substituted aryl; R5is H, alkyl, —CH(R7)R8, —C(CH2)nCO2R9, —C(CH3)2CO2R9, CH(R7)(CH2)nCO2R9, or —CH(R7)C6H4CO2R9; R6is alkylene; R7is H, alkyl, aryl, aralkyl, cycloalkyl, phthalic acid, or Q-alkyl;Q isR8is —CO2R11, —CONHR11, tetrazole, or —PO3R11; R9is H, alkyl, aryl, or aralkyl; W is O, N, or S; R11is H, alkyl, aryl, or aralkyl; n=1-6; or a pharmaceutically acceptable salt or ester form thereof.
REFERENCES:
patent: 5457109 (1995-10-01), Antonucci et al.
patent: 5610153 (1997-03-01), Buhlmayer et al.
patent: 5847008 (1998-12-01), Doebber et al.
patent: 6110963 (2000-08-01), Malamas
patent: 6136794 (2000-10-01), Cook et al.
patent: 6166069 (2000-12-01), Malamas et al.
patent: 6232322 (2001-05-01), Malamas et al.
patent: 6262044 (2001-07-01), M.o slashed.ller et al.
patent: 6369072 (2002-04-01), Malamas et al.
patent: 6391897 (2002-05-01), Malamas et al.
patent: 6509360 (2003-01-01), Malamas et al.
patent: 6589970 (2003-07-01), Commons et al.
patent: 6599925 (2003-07-01), Elokdah et al.
patent: 6599929 (2003-07-01), Cho et al.
patent: 6787556 (2004-09-01), Hargreaves et al.
patent: 6800654 (2004-10-01), Mayer et al.
patent: 6844358 (2005-01-01), Malamas et al.
patent: 7019026 (2006-03-01), Andersen et al.
patent: 2003/0018067 (2003-01-01), Elokdah et al.
patent: 2003/0032626 (2003-02-01), Mayer et al.
patent: 2003/0125371 (2003-07-01), Elokdah et al.
patent: 2005/0070587 (2005-03-01), Elokdah et al.
patent: WO 99/43651 (1999-09-01), None
patent: WO 99/43672 (1999-09-01), None
patent: WO 99/58519 (1999-11-01), None
patent: WO 01/12187 (2001-02-01), None
patent: WO 03/031409 (2003-04-01), None
patent: WO 03/087087 (2003-10-01), None
“Novel Benzofuran and Benzothiophen Biphenyls as Inhibitors of Protein Tyrosine Phosphatase 1B with Antihyperglycemic Properties”, Malamas et al., Journal of Medicinal Chemistry, 2000, 43(7), 1293-1310.
“Protein-Tyrosine Phosphatase !B (PTP1B): a Novel Therapetuic Target for Type 2 Diabletes Mellitus, Obesity and Related States of Insulin Resistance”, Goldstein BJ, abstract, Curr Drug Targets Immune Endor Metabol Disord. Nov. 2001; 1(3):265-75.
“Obestiy and INsulin Resistance”, Kahn et al., J Clin Invest, Aug. 15, 2000; 106(4): 473-481.
“NO Attenuates Insulin Signaling and Motility in Aortic Smooth Muscle Cells Via Protein Tyrosine Phosphatase !B-Meidated Mechanism”, Sreejayan et al., Arterioscler Thromb Vasc Biol., 2002;22:1086-1092.
“PTP-1B is an essential positive regulator of platelet integrin signaling”, Arias-Salgado, JCB, vol. 170, No. 5, 2005.
Paquet et al., Biochem. J., 1998, 333, pp. 591-599.
Nordt et al., The Journal of Clinical Endocrinology & Metabolism, 85(4), 1563-1568 (2000).
Aznar et al., Haemostasis, 24, 243-251 (1994).
Carmeliet et al., Journal of Clinical Invest., 92, 2756-2760 (1993).
Daci et al., Journal of Bone & Mineral Research, 15(8), 1510-1516 (2000).
Biemond et al., Circulation, 91(4), 1175-1181 (1995).
Levi, et al., Circulation, 85(1), 305-312 (1992).
Rocha, et al., Fibrinolysis, 8, 294-303 (1994).
Reilly et al., Arteriosclerosis & Thrombosis 11, 1276-1286 (1991).
Krishnamurti et al., Blood, 69(3), 798-803 (1987).
Charlton, P., Expert Opinion on Investigational Drugs vol. 6, No. 5, pp. 539-554.
Malamas, M. S., et al., Journal of Medicinal Chemistry (2000) 43(7), 1293-1310.
Crandall, D. L. et al., “Characterization and comparative evaluation of a structurally unique PAI-1 inhibitor exhibiting oral in-vivo efficacy,”Journal of Thrombosis and Haemostasis, Mar. 17, 2004, 2: 1-7.
Kwon Brian
Woodcock & Washburn LLP
Wyeth
LandOfFree
Aryloxy-acetic acid compounds useful as inhibitors of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aryloxy-acetic acid compounds useful as inhibitors of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryloxy-acetic acid compounds useful as inhibitors of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3822781